The efficacy and safety of tenecteplase compared with alteplase in adult patients with acute ischemic stroke: an updated systematic review and meta-analysis of ten randomized controlled trials

Author:

Chinniah KarthikeyanORCID,Shadakkathulla Nizamudeen

Abstract

Abstract Background Alteplase (tPA) is the only thrombolytic agent approved by the USFDA for acute ischemic stroke (AIS). Various randomized controlled trials (RCTs) have reported that Tenecteplase (TNK) is non-inferior to tPA resulting in its approval in various countries. We compared the efficacy and safety of TNK with tPA in adult patients with AIS by performing an updated systematic review and meta-analysis of recently published RCTs. Thus, PubMed and Cochrane databases were searched for RCTs until April 27, 2023. Data is represented as log-odds ratio (logOR) with 95% confidence interval (CI). The efficacy outcome measures included early neurological improvement (ENI), recanalization, functional outcomes at 90-days (modified Rankin Scale (mRS) 0–1 and 0–2), any intracranial hemorrhage (ICH), symptomatic ICH, and mortality within 90-days. Results Ten RCTs involving 5105 adult patients with AIS were included. The rates of ENI (logOR: 0.11; 95%CI: − 0.02, 0.23; p-value: 0.09), recanalization (logOR: 0.33; 95%CI: − 0.02, 0.68; p-value: 0.07), mRS 0–1 at 90-days (logOR: 0.09; 95%CI: − 0.02, 0.21; p-value: 0.11), and mRS 0–2 at 90-days (logOR: 0.07; 95%CI: − 0.29, 0.44; p-value: 0.70) were comparable among TNK and tPA. Similarly, TNK and tPA were comparable regarding any ICH (logOR: 0.06; 95%CI: − 0.11, 0.24; p-value: 0.47), symptomatic ICH (logOR: − 0.14; 95%CI: − 0.47, 0.20; p-value: 0.42), and all-cause mortality (logOR: − 0.04; 95%CI: − 0.23, 0.15; p-value: 0.70). Conclusions Based on the included RCTs, TNK is comparable to tPA regarding efficacy and safety. Thus, TNK can be recommended as an alternative to tPA in adult patients with AIS.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),General Neuroscience,Pshychiatric Mental Health,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3